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INTRODUCTION
Stone disease is an increasingly prevalent condition throughout the world with a global average lifetime prevalence of around 10% (range 8 to 22%) (1) (2) (3) (4) (5) . On average, the recurrence rate is 50% within 5 years but some patients form stones much more frequently (6) . Treatment costs are high (7, 8) . Epidemiological studies have linked stone disease to obesity, metabolic syndrome, and also to fluid, protein and salt intake (9) (10) (11) . Lifestyle changes, dietary strategies and medical therapy have been shown to reduce recurrence (12) . These preventive strategies reduce the recurrence rate and are cost effective (13) (14) (15) . In order for prevention strategies to be effective an early and objective measure of response would help to encourage patient compliance. Various mathematical algorithms have been developed to analyse urine biochemistry to determine risk (16) (17) (18) (19) (20) (21) (22) (23) but none has been adopted universally. In this study we applied the PSF (probability of stone formation) algorithm (22, 23) to data from a cohort of Brazilian pa- tients before and during treatment to investigate the changes in their PSF scores. The aim was to confirm that PSF changed appropriately following medical therapy and to determine whether PSF might be used to help tailor treatment for recurrent stone formers.
MATERIALS AND METhODS
Data were collected on 26 Brazilian stone--formers attending Urolithiasis Metabolism Outpatient Clinics -Paulista State University (UNESP), São Paulo, Brazil. This study was approved by the Research Ethics Committee of the School of Medicine of Botucatu, UNESP (Protocol CEP 3331-2009) and all patients gave their informed consent. Details of patient age, gender, weight and height were recorded. A baseline 24-hour urine sample was collected from each patient prior to treatment for a full metabolic evaluation. PSF analysis included 7 urinary parameters: voided volume, oxalate, calcium, urate, pH, citrate and magnesium. The PSF algorithm is based on a Bayesian mathematical formula which weights each of the contributory risk factors according to a set of "risk curves" derived from frequency distributions in a large number of idiopathic stone-formers and their controls (22, 23) . The PSF algorithm produces values between 0 and 1 for 5 different patterns of stone (calcium oxalate, urate, calcium phosphate, mixed calcium oxalate and urate and mixed calcium oxalate and calcium phosphate). PSF scores greater than 0.5 suggest a high stone risk (23) . All patients in this cohort received some form of medication for treating stone disease, many received polypharmacy. Details of the patients' medication were recorded. All patients were advised to increase their fluid intake in order to mantain a colorless urine output (at least 2 liters per day). A repeat 24-hour urine sample was performed for PSF calculation during treatment. Repeat 24-hour urine collections were performed a minimum of 4 months after treatment commenced.
RESULTS
The cohort included 26 patients (15 women and 11 men) with a mean age of 45.4 years (median 46, range 28-67) and a mean BMI of 27.8 (median 28.1, range 15.6 -39.9). All patients had complete values for the 7 parameters required for the PSF calculation before and during treatment ( Table-1) .
The majority of patients were high risk for calcium stones before treatment according to the PSF scores. For calcium oxalate (p = 0.0004), mixed calcium oxalate/calcium phosphate (p = 0.006) and calcium phosphate stone risks (p = 0.002) there were significant overall reductions in PSF score within the cohort following treatment (paired t-test) ( Figure-1 ). There was only one patient in the cohort with a high PSF score (> 0.5) for uric acid stones (patient 3). This patient's PSF score dropped to almost 0 after treatment. At baseline 20 of the 26 patients (77%) had at least one high PSF score amongst their 5 PSF scores (> 0.5) ( Table-2) . Of the 26 patients, 17 (65%) showed an reduction in their PSF profiles with an aggressive medical treatment regimen (Table-3 ). 11 patients (42%) changed from a high risk (PSF > 0.5) to a low risk (PSF < 0.5) in at least one of their PSF scores and 6 patients reduced their risk score but did not change risk category. Six (23%) patients remained in a high risk category (> 0.5) in both assessments (Table-2) . Two patients showed an increase in risk between tests -one because of a marked increase in urinary oxalate (patient 19) and the other because of a major decrease in urine volume (patient 26). One patient was in the low risk category in both tests (Table-2) .
DISCUSSION
This paper highlights several points about the metabolic management of stone formers and use of the PSF algorithm. The majority of this small cohort of Brazilian patients was found to have a high PSF score prior to prophylactic treatment. This suggests that the algorithm developed in British populations is applicable in a population with a different genetic background and environmental risk factors. In this connection, it has also been shown to apply to calculation of the biochemical risk of forming stones in populations from the oil-rich states of the Middle East where urine composition is very different from that in the West and, based on this study, in Brazil (5). Furthermore, the majority of patients demonstrated a significant reduction in PSF score following medical therapy suggesting that the PSF score might be an early surrogate for treatment response. 
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As demonstrated by the patients in this cohort, there are often abnormalities in 24-hour urine collections and it is difficult for the treating physician to know which are most significant and which to treat. The PSF algorithm weights each of the parameters to produce an overall risk. Although single factors may be within normal or just outside normal limits they can alter the overall risk profile significantly.
These data also emphasise how important it is to determine which aspects of a patient's urinary profile contribute most to stone risk. Several patients in this cohort remained at high risk despite medical treatment. For the most part, this was due to persistently high urinary oxalate levels which will not be addressed by the routine pharmacotherapy prescribed in this cohort.
The limitations of this study are its small cohort size, the use polypharmacy which makes analysis of effect of individual drugs impossible, a single 24 hour urine collection before and after treatment and the absence of data on dietary influence or details of stone type. Larger, more comprehensive studies are required to validate further the use of PSF scoring in the management of stone disease over longer periods of treatment. Ideally, this should be correlated with a reduction in stone recurrence rate.
In order to reduce stone risk a holistic approach to risk determination must be taken and a personalized treatment plan including lifestyle, dietary advice, and pharmacotherapy should be advocated. Ideally, PSF score should be used in conjunction with dietary and lifestyle information to create a personalized treatment plan. Patients should be reviewed with repeat tests to check compliance.
CONCLUSIONS
In conclusion, the PSF score changed from high to low risk following medical treatment in the majority of patients in this cohort. This makes PSF score a potentially useful short--term surrogate marker to assess stone risk. PSF score may be used as part of a more comprehensive evaluation of stone risk to reduce the likelihood of recurrent stones in individual patients.
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